Passive Immunization with Allergen-Specific Antibodies.
Vaccines against Allergies
Current topics in microbiology and immunology, June 2011
Sabine Flicker, Elisabeth Gadermaier, Christoph Madritsch, Rudolf Valenta
The induction of allergen-specific IgG antibodies has been identified as a major mechanism responsible for the reduction of allergic inflammation in allergic patients treated by allergen-specific immunotherapy. Several studies suggest that allergen-specific IgG antibodies induced by vaccination with allergens block mast cell and basophil degranulation, IgE-facilitated allergen presentation to T cells and IgE production. The availability of recombinant allergens and technologies for the production of recombinant human antibodies allows engineering of allergen-specific antibodies which can be used for passive immunization (i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis). This chapter summarizes data supporting the possible use of allergen-specific antibodies for treatment and prophylaxis. Finally, concrete approaches for the treatment and prevention of allergy based on blocking antibodies are envisioned.
|Practitioners (doctors, other healthcare professionals)||1||100%|
|Readers by professional status||Count||As %|
|Student > Bachelor||5||33%|
|Student > Postgraduate||2||13%|
|Student > Ph. D. Student||2||13%|
|Student > Master||2||13%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||10||67%|
|Biochemistry, Genetics and Molecular Biology||1||7%|
|Agricultural and Biological Sciences||1||7%|
|Arts and Humanities||1||7%|